Drugs / In-111-Zevalin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01510184 Background | Apr 2012 → Oct 2014 | diffuse large B-cell lymphoma, follicular lymphoma | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | In-111-Zevalin | “In-111-Zevalin administered by intravenously.” NCT01510184 ↗ |
| Route | Intravenous | “In-111-Zevalin administered by intravenously.” NCT01510184 ↗ |